Ventricular tachycardia storm management in a COVID-19 patient: a case report

Gianfranco Mitacchione1, Marco Schiavone1, Alessio Gasperetti1

  • 1Department of Cardiology, Luigi Sacco Hospital, University of Milan, Milan, Italy.

Insights

Coronavirus disease 2019 (COVID-19) can trigger dangerous ventricular arrhythmias and electrical storm in patients with heart conditions. This case report details a successful ablation for a patient experiencing ventricular tachycardia storm due to COVID-19.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Electrophysiology

Background:

  • Myocardial involvement is a known complication of COVID-19.
  • Cardiac arrhythmias, including malignant ventricular arrhythmias and electrical storm, are potential cardiovascular manifestations.
  • The specific presentation of these arrhythmias in COVID-19 patients requires further investigation.

Observation:

  • A 68-year-old patient with coronary artery disease and heart failure presented with COVID-19 pneumonia.
  • The patient experienced ventricular tachycardia storm with multiple implantable cardioverter defibrillator shocks as the primary cardiac manifestation.
  • A successful catheter ablation using a remote navigation system was performed.

Findings:

  • This is the first reported case of COVID-19 pneumonia presenting with ventricular tachycardia storm as the main cardiac manifestation.
  • COVID-19 can precipitate severe ventricular arrhythmias in patients with pre-existing ischemic cardiomyopathy.
  • Successful ablation provided a favorable outcome for the patient.

Implications:

  • Highlights the critical need to consider cardiac arrhythmias in COVID-19 patients, especially those with underlying heart disease.
  • Suggests that COVID-19 may act as a trigger for electrical storm in susceptible individuals.
  • Emphasizes the efficacy of substrate-based VT ablation in managing these complex cases.
Abstract

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
293
Increased pulse rate01:17

Increased pulse rate

Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
931
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
309
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
254
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
93
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
164